Phaseline

Targets › ICAM1

ICAM1 (Intercellular adhesion molecule 1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Ophthalmology; next expected readout Dec 2026.

Cell adhesion molecule that functions as a receptor ligand of the signaling receptor ITGAL:ITGB2/LFA-1 (lymphocyte-function associated (LFA) molecule 1) ensuring leukocyte cell-cell adhesion, by providing a calibrated system to namely adjust T-cell killing to the antigen stimulation strength. Also functions as a ligand receptor of the signaling receptor ITGAM:ITGB2/MAC-1 ensuring adhesion between stimulated…. (UniProt, P05362)

Open in Phaseline: the race on ICAM1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Oculislicaminlimab
Anti-ICAM-1 antibody
ICAM1Phase 2Dry Eye Disease (DED)Dec 2026

Conditions

Dry Eye Disease (DED) (1)

Modalities

antibody (1)

Companies

Oculis (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.